Skip to content
Screener

Crinetics Pharmaceuticals CRNX Operating Cash Flow

Operating Cash Flow at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$145.8M+125%
Corcept Therapeutics logo
Corcept TherapeuticsCORT
$33.54M-23.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$197.28M+1.0%
MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
-$20.21M+10.9%
XER
Xeris Biopharma Holdings, Inc.XERS
$8.26M+4,440%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$113.98M-118%

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$8.9B+233%
Enterprise value$8.84B+231%
P/S492.8×-1,427×

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:21 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001658247-26-000040
Line itemThree months ended / March 31, 2026Three months ended / March 31, 2025
Accounts payable and accrued expenses, compensation and related expenses, and other liabilities(12,064)(1,356)
Deferred revenue(428)(361)
Operating lease liabilities(685)(903)
Net cash used in operating activities(124,703)(88,452)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of investment securities(554,428)(391,204)
Proceeds from sales and maturities of investment securities302,889306,482
Purchases of property and equipment(820)(1,239)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Crinetics Pharmaceuticals's operating cash flow?
Crinetics Pharmaceuticals (CRNX) reported operating cash flow of -$124.7M in Q1 2026.
How has Crinetics Pharmaceuticals's operating cash flow changed year-over-year?
Crinetics Pharmaceuticals's operating cash flow decreased by 41.0% year-over-year, from -$88.45M to -$124.7M.
What is the long-term trend for Crinetics Pharmaceuticals's operating cash flow?
Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's operating cash flow has grown at a 43.7% compound annual growth rate (CAGR), from -$88.59M to -$377.92M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Crinetics Pharmaceuticals's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude